PRDX2

Across TCGA pan-cancer cohorts, PRDX2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRDX2 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PRDX2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRDX2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, COAD, and GBM are the cancer types where PRDX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.926	0.676	.001	26	view →
COAD	DFS	Median	III,IV	1.000	0.841	.041	6	view →
GBM	OS	Median	All	0.502	0.275	.003	5	view →
LSCC	DFS	Tertile	All	1.000	0.372	.018	2	view →
HNSC	DFS	Quartile	III,IV	0.920	0.719	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRDX2–CCRCC (DFS)

Open the CCRCC breakdown →